FOLH1 and pachyonychia congenita: Furthermore, Sartor et al. demonstrated in their Phase III clinical trial of 177Lu-PSMA-617 that ~86.6% (n = 869/1003) of mCRPC patients imaged were PSMA-positive, indicative of the high prevalence of PSMA-positive lesions at later stages of PC [68].